
**PROFIT GUIDANCE FOR THE SECOND HALF YEAR AND FULL YEAR ENDED 31
DECEMBER 2022**

The Board of Directors (the "**Board**") of OUE Lippo Healthcare Limited ("**Company**", together with its subsidiaries, "**Group**") wishes to advise shareholders that the Group is expected to report a higher net loss after non-controlling interest for the second half-year ended 31 December 2022 ("**2H2022**") as compared to the corresponding period in 2021, based on a preliminary assessment of the Group's 2H2022 unaudited consolidated financial results.

The expected net loss after non-controlling interest for 2H2022 is mainly attributable to net fair value losses relating to investment properties and impairment of investment in associate and joint ventures. The value of the Group's assets and investments have been adversely impacted by global macroeconomic headwinds, foreign exchange volatility, rising interest rates and an inflationary environment.

Notwithstanding the above, the Company expects to report an overall net profit after non-controlling interest in respect of the Group for the full year ended 31 December 2022 ("**FY2022**"). However, the Company expects to report a lower overall net profit after non-controlling interest for FY2022 compared to the preceding full year ended 31 December 2021 ("**FY2021**") as the FY2021 results included a one-off gain arising from the conversion of a shareholder loan in FY2021.

The Company is in the process of finalising its unaudited financial results for 2H2022 and FY2022. Further details of the Group's financial results will be disclosed when the Company announces its unaudited financial results for 2H2022 and FY2022 before 28 February 2023.

In the meantime, shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
21 February 2023

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

6 Shenton Way, #10-10, OUE Downtown, Singapore 068809

T: +65 6578 9188 F: 64794647 Web: www.ouelh.com